Advertisement

Comprehensive Analysis of MHC Ligands in Clinical Material by Immunoaffinity-Mass Spectrometry

  • Kie Kasuga
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1023)

Abstract

Major histocompatibility complexes (MHC) are expressed on antigen-presenting cells (APC) that display peptide antigens. This is a crucial step to activate a T-cell response. Since immunogenic ligand of MHC is closely related with autoimmunity, inflammatory diseases, and cancer, comprehensive analysis of MHC ligands (the so-called Ligandome) is essential to unveil disease pathogenesis. Recently, immunotherapies such as vaccination have been focused on as new therapies of cancer, HIV, and infectious diseases. Therefore, the importance of comprehensive analysis of MHC ligands is increasing. Mass spectrometry has been the core technology of ligand identification since the 1990s. The sensitivity of mass spectrometers has been improved dramatically in recent years; thus, it enables to identify MHC ligands in clinical materials. This chapter lays out the workflow of MHC ligand identification in clinical materials, especially human bronchoalveolar (BAL) cells. MHC-ligand complexes are enriched by immunoaffinity extraction and captured ligand peptides are identified by LC-MS/MS. MHC class II ligand in BAL cells is described in this text; however, this approach is applicable to MHC class I and other clinical materials such as tissues.

Key words

Major histocompatibility complexes (MHC) Immunoaffinity extraction Ligand Bronchoalveolar lavage (BAL) Comprehensive analysis 

Notes

Acknowledgments

Dr. Stefan Stevanović (Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany) and Dr. Rui Mamede Branca (Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory Stockholm) are gratefully acknowledged for helpful discussion. The author is a VINNMER fellow supported via VINNMER Marie Curie Chair—a VINNOVA programme cofounded by Marie Curie Actions.

References

  1. 1.
    Klein J (1986) Natural History of the Major Histocompatibility Complex, 99th edn. Wiley, New YorkGoogle Scholar
  2. 2.
    Rammensee HG (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7:85–96PubMedCrossRefGoogle Scholar
  3. 3.
    Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27–47PubMedCrossRefGoogle Scholar
  4. 4.
    Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, Paharkova-Vatchkova V, Eng J, Caldwell H, Yates JR 3rd, Rudensky AY (2001) In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol 31:1485–1494PubMedCrossRefGoogle Scholar
  5. 5.
    Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296–306PubMedCrossRefGoogle Scholar
  6. 6.
    Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E, Grey HM, Sette A (1992) Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256:1817–1820PubMedCrossRefGoogle Scholar
  7. 7.
    Kasuga K, Branca RM, Wahlstrom J, Wheelock AM, Eklund A, Grunewald J, Lehtio J (2011) High sensitivity approach for identification of MHC Class II-bound peptides from bronchoalveolar lavage cells in sarcoidosis patients. Am J Respir Crit Care Med 183:A6404Google Scholar
  8. 8.
    Horlock C, Stott B, Dyson J, Ogg G, McPherson T, Jones L, Sewell AK, Wooldridge L, Cole DK, Stebbing J, Savage P (2009) ELISPOT and functional T cell analyses using HLA mono-specific target cells. J Immunol Methods 350:150–160PubMedCrossRefGoogle Scholar
  9. 9.
    Eklund A, Blaschke E (1986) Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. Thorax 41:629–634PubMedCrossRefGoogle Scholar
  10. 10.
    Wahlstrom J, Dengjel J, Winqvist O, Targoff I, Persson B, Duyar H, Rammensee HG, Eklund A, Weissert R, Grunewald J (2009) Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol 133:353–363PubMedCrossRefGoogle Scholar
  11. 11.
    Mano N, Abe K, Goto J (2006) Immunoaffinity extraction of a peptide modified by a small molecule. Anal Biochem 349:254–261PubMedCrossRefGoogle Scholar
  12. 12.
    Friede T, Gnau V, Jung G, Keilholz W, Stevanovic S, Rammensee HG (1996) Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim Biophys Acta 1316:85–101PubMedCrossRefGoogle Scholar
  13. 13.
    Nag B, Passmore D, Deshpande SV, Clark BR (1992) In vitro maximum binding of antigenic peptides to murine MHC class II molecules does not always take place at the acidic pH of the in vivo endosomal compartment. J Immunol 148:369–372PubMedGoogle Scholar
  14. 14.
    Ma B, Zhang K, Hendrie C, Liang C, Li M, Doherty-Kirby A, Lajoie G (2003) PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom 17:2337–2342PubMedCrossRefGoogle Scholar
  15. 15.
    Chen P, Rayner S, Hu KH (2011) Advances of bioinformatics tools applied in virus epitopes prediction. Virol Sin 26:1–7PubMedCrossRefGoogle Scholar
  16. 16.
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219PubMedCrossRefGoogle Scholar
  17. 17.
    Donnes P, Elofsson A (2002) Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 3:25PubMedCrossRefGoogle Scholar
  18. 18.
    Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF (2004) Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 101(26):9528–9533PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kie Kasuga
    • 1
  1. 1.Science for Life Laboratory, Department of Oncology–PathologyKarolinska InstitutetStockholmSweden

Personalised recommendations